The cost‐effectiveness of sacral nerve stimulation (SNS) for the treatment of idiopathic medically refractory overactive bladder (wet) in the UK

Publisher： John Wiley & Sons Inc

E-ISSN： 1464-410x|116|6|945-954

ISSN： 1464-4096

Source： BJU INTERNATIONAL, Vol.116, Iss.6, 2015-12, pp. : 945-954

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Current Information on Sacral Neuromodulation and Botulinum Toxin Treatment for Refractory Idiopathic Overactive Bladder Syndrome: A Review

By  

Urologia Internationalis, Vol. 84, Iss. 3, 2010-04 ,pp. : 245-253

Karger

Access to resources Recommend Favorite

The cost-effectiveness of solifenacin vs. trospium in the treatment of patients with overactive bladder in the German National Health Service

By Nazir J.   Hart W.M.  

Journal of Medical Economics, Vol. 17, Iss. 6, 2014-06 ,pp. : 408-414

Informa Healthcare

Access to resources Recommend Favorite

Cost-effectiveness analysis of solifenacin versus oxybutynin immediate-release in the treatment of patients with overactive bladder in the United Kingdom

By Hart Warren Mark   Abrams Paul   Munro Vicki   Retsa Peny   Nazir Jameel  

Journal of Medical Economics, Vol. 16, Iss. 10, 2013-10 ,pp. : 1246-1254

Informa Healthcare

Access to resources Recommend Favorite

Botulinum toxin: historical perspective and treatment of neurogenic and idiopathic overactive bladder

By Mulligan Daniel   Bologna Raymond  

Therapy, Vol. 6, Iss. 2, 2009-03 ,pp. : 165-175

Future Medicine

Access to resources Recommend Favorite

Cost-effectiveness of licensed treatment options for restless legs syndrome in the UK and Sweden

By Lees M.   Roberts G.   Tabberer M.   DasGupta R.   Finnern H. W.    

Current Medical Research and Opinion, Vol. 24, Iss. 10, 2008-10 ,pp. : 2919-2930

Informa Healthcare

Access to resources Recommend Favorite